Clinical Outcomes in COVID-19 Patients with Liver Disease

Patients with underlying liver disease, especially those with cirrhosis, are at increased risk for poor outcomes with COVID-19.

COVID-19 is associated with elevated liver tests in patients without liver disease (LD; NEJM JW Gastroenterol Jun 2020 and Clin Gastroenterol Hepatol 2020 Apr 10; [e-pub]). However, the clinical impact of COVID-19 in patients with underlying LD is unclear.

Now, investigators have analyzed data from the TriNETX Research Network database on 2780 COVID-19 patients (≥10 years of age); 250 had LD, including 50 with cirrhosis. Patients with and without LD were propensity-matched according to comorbidities, age, and race.

Rates of elevated liver chemistries were similar in patients with and without LD. However, during 30 days following COVID-19 diagnosis, patients with LD had higher risk for mortality than those without LD (relative risk, 3.0; P<0.0…

Reviewing Author

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Clinical Outcomes in COVID-19 Patients with Liver Disease

Topics

Reviewing Author